WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 402210
Description: CDKI-83 is a potent CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 <1 μM, and is capable of inducing apoptosis in A2780 human ovarian cancer cells as determined by the activated caspase-3, Annexin V/PI double staining and accumulated cells at the sub-G1 phase of cellcycle. The research results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent.
MedKoo Cat#: 402210
Chemical Formula: C21H23N7O3S2
Exact Mass: 485.13038
Molecular Weight: 485.58
Elemental Analysis: C, 51.94; H, 4.77; N, 20.19; O, 9.88; S, 13.21
CDKI-83 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: CDKI83; CDKI-83; CDKI 83.
IUPAC/Chemical Name: 4-(4-methyl-2-(methylamino)thiazol-5-yl)-2-((4-methyl-3-(morpholinosulfonyl)phenyl)amino)pyrimidine-5-carbonitrile
InChi Key: SSEDQERECATUBR-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H23N7O3S2/c1-13-4-5-16(10-17(13)33(29,30)28-6-8-31-9-7-28)26-20-24-12-15(11-22)18(27-20)19-14(2)25-21(23-3)32-19/h4-5,10,12H,6-9H2,1-3H3,(H,23,25)(H,24,26,27)
SMILES Code: N#CC1=CN=C(NC2=CC=C(C)C(S(=O)(N3CCOCC3)=O)=C2)N=C1C4=C(C)N=C(NC)S4
The following data is based on the product molecular weight 485.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Liu X, Lam F, Shi S, Fischer PM, Wang S. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. 2012 Jun;30(3):889-97. doi: 10.1007/s10637-011-9641-5. Epub 2011 Feb 18. PubMed PMID: 21331744.
The following activity data of CDKI-83 was directly copied from Invest New Drugs. 2012 Jun;30(3):889-97: